CervoMed to present nfvPPA biomarker data in late-breaking session at ISFTD 2026

CervoMed Inc. said on September 10, 2026 that data from the Phase 2a trial of neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA) will be featured in a late-breaking oral presentation at the International Society of Frontotemporal Dementias Annual Meeting, to be held in Philadelphia, Pennsylvania from October 8 to 11, 2026.¹

The company noted it recently completed enrollment in the Phase 2a trial of neflamapimod for nfvPPA.¹ The abstract accepted for the late-breaking session was based on 12-week biomarker data from the trial's first eight participants, and the presentation will cover two plasma markers, neurofilament light chain and glial fibrillary acidic protein, drawn from a larger group of at least 22 participants.¹

The study's design is meant to assess safety, pharmacokinetics, and clinical effects of neflamapimod in nfvPPA patients, with 25 participants enrolled across academic medical centers in the U.S. and U.K.¹

The presentation is titled "Initial Biomarker Results from a Phase 2a Clinical Trial of Neflamapimod in Patients with Nonfluent Variant Primary Progressive Aphasia (NCT07033481)" and is scheduled for the Plenary 6 (Hot Topics) session on Sunday, October 11, 2026, from 8:30 a.m. to 10:30 a.m.¹

nfvPPA is a subtype of frontotemporal dementia with an estimated 10,000 to 15,000 patients in the U.S. and 15,000 to 20,000 in the E.U., and currently no approved treatments in either region.¹ Neflamapimod received Orphan Drug Designation from the FDA for frontotemporal dementia in 2024.¹

Separately, the company said it expects to dose the first patient in its EXPERTS-ALS Phase 2a trial during the fourth quarter of 2026.¹